Tag: Biogen

Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU

businessnewstoday- February 13, 2024

In a landmark decision, the European Commission (EC) has authorized Biogen Inc.'s SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents ... Read More

Biogen reprioritizes Alzheimer’s disease resources, discontinues ADUHELM development

businessnewstoday- January 31, 2024

Biogen Inc. (Nasdaq: BIIB), a leading pharmaceutical company, today announced a strategic reprioritization of its resources in Alzheimer’s disease (AD), a key therapeutic area expected ... Read More

Sage Therapeutics, Biogen get ZURZUVAE FDA approval for postpartum depression treatment

businessnewstoday- August 5, 2023

Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults ... Read More

Biogen to expand portfolio with $7.3bn acquisition of Reata Pharmaceuticals

businessnewstoday- July 30, 2023

Biogen Inc. (Nasdaq: BIIB) is set to acquire Reata Pharmaceuticals, Inc. (Nasdaq: RETA) for $172.5 per share in cash, amounting to an enterprise value of ... Read More

Eisai, Biogen secure Leqembi FDA accelerated approval for Alzheimer’s disease

Raghuram Kadari- January 9, 2023

Eisai and Biogen have secured the approval of the US Food and Drug Administration (FDA) for their jointly developed Leqembi (lecanemab-irmb) under the accelerated approval ... Read More

Sage Therapeutics secures $3.1bn worth licensing deal for zuranolone and SAGE-217 with Biogen

pharmanewsdaily- November 29, 2020

Sage Therapeutics has secured a global collaboration and licensing deal worth up to $3.1 billion with Biogen for two of its drug candidates intended for ... Read More

FDA accepts BLA for Lucentis referencing ophthalmology biosimilar SB11

pharmanewsdaily- November 19, 2020

Samsung Bioepis and Biogen said that the US Food and Drug Administration (FDA) has accepted for review the biologics license application for SB11, a proposed ... Read More

Mylan gets favorable court decision in Biogen’s Tecfidera patent case

pharmanewsdaily- June 19, 2020

Dutch generic drugmaker Mylan said that the US District Court for the Northern District of West Virginia has invalidated Biogen's Tecfidera patent U.S. Patent No. ... Read More

Biogen to acquire Pfizer neurology drug in a deal that could reach $600m

pallavi123- March 12, 2018

Pharma acquisition news : US biotechnology company Biogen has made a deal with Pfizer to buy the latter’s neurology drug candidate PF-04958242, which is being ... Read More